452. RegenVOX - Translational Exploitation Strategy for Stem Cell-Based Tissue-Engineered Laryngeal Implants Undergoing Phase I/II Clinical Trial
Emily J Culme-Seymour(GlaxoSmithKline (United Kingdom)), Chris Mason(Oak Ridge National Laboratory), Jeff Round(University College London), Sophie Wilson(University College London), Owen Bain(London Centre for Nanotechnology), Gareth Ambler(University College London), Eugene Omakobia(University College London), Helen Knowles(University College London), Susan Tebbs(MRC Clinical Trials Unit at UCL), Carla Carvalho(The Royal Free Hospital), Mark W. Lowdell(Royal Free London NHS Foundation Trust), Kim Champion(University College London), Martin Birchall(University of Bristol)
Cited by 0
Related Papers
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276
A rat decellularized small bowel scaffold that preserves villus-crypt architecture for intestinal regeneration
|Biomaterials|2012|210
Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential
|Regenerative Medicine|2011|144